Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
The authors argue that recommendations for the expanded use of statins to stave off cardiovascular disease are NOT supported by the evidence.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
British Medical Journal: Something is rotten at the heart of FDA / Glaxo faces class action suit Sun, 5 Dec 2004 “Something is rotten at the heart of the FDA.” That’s the opening of an editorial in the British Medical Journal. [1] Indeed, there is something rotten at the heart…
Eli Lilly Prozac Documents: What do They Reveal? Thu, 27 Jan 2005 A report in the BMJ (formerly the British Medical Journal) that relied on internal Eli Lilly documents to challenge Lilly’s claims about the safety of Prozac has stirred a prickly hornet’s nest. [1] The documents show, among other…
A Lobbying Campaign for Screening Children for Mental Problems–a Gimmick Aimed at Increasing PhRMA Profits Wed, 11 May 2005 The big guns of America’s mental health establishment — including the American Psychiatric and Psychological Associations and the National Alliance for the Mentally Ill — are making united front in support…
Ethics / Science of ARDS Controversy Continues – J Medical Ethics-BMJ Thu, 6 Oct 2005 The ethics and science of a controversial clinical trial sponsored by the US government and conducted at multiple sites by the ARDS Network comprising of prestigious academic medical centers is the subject of a continuing…
FDA to review “missing” drug company documents Fri, 31 Dec 2004 Related Link: Peter Breggin, MD RE: Eli Lilly’s Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance In the final hours of 2004, an investigative reporter for the British Medical Journal obtained long “missing” Eli…
Recent developments in gene transfer research: risk and ethics Mon, 10 Jan 2005 An analysis by Dr. Jonathan Kimmelman, in the British Medical Journal provides an illuminating, clearly articulated discussion about the ethical dilemmas that challenge gene transfer experiments – essentially a kind of human genetic engineering involving somatic cells,…
Bush Plans to Screen Whole US Population for Mental Illness – BMJ Thu, 24 Jun 2004 A second article in the British Medical Journal discloses additional evidence uncovered by Allen Jones, the whistle blower from the Pennsylvania Inspector General’s Office. The first BMJ article focused on the Texas Medication Algorithm…